Clinical trials
Patient clinical trials
Below are recruiting patient clinical trials, each written for real people, not researchers. We’re tracking 14,836 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02675959RecruitingPhase 2
Transplant with defibrotide for sickle cell disease
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
Los Angeles, CaliforniaAges 6 months–21 years - NCT06763341RecruitingPhase 1
AOH1996 for relapsed or refractory acute myeloid leukemia
This trial tests a new drug, AOH1996, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if this drug is safe and helps control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT07727434Recruiting
Stress and Anxiety in People Having Biopsy for Bone or Soft Tissue Cancer
This study looks at how stress and anxiety levels change in people who are about to have a biopsy for a possible bone or soft tissue tumor. The goal is to better understand the emotional impact of waiting for results and starting treatment.
IstanbulAges 18 years+ - NCT06999122Recruiting
Testing a new helmet-style brain scanner for stroke bleeding
This trial tests a new type of brain scanner (similar to a helmet) that looks for bleeding in the brain without radiation. It is for people who have had stroke-like symptoms in the last 24 hours and have not yet received treatment.
Los Angeles, CaliforniaAges 22 years+ - NCT07701486RecruitingPhase 1/Phase 2
Testing more frequent VCN-01 with standard chemo for new pancreatic cancer
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
Madrid, MadridAges 18 years+ - NCT07078383Recruiting
Study of the Rapidlink device for aorta repair
This trial tests a device called Rapidlink that helps repair blood vessels branching off the aorta during open heart surgery. It may be an option if you need open surgery to fix your thoracic aorta.
Los Angeles, CaliforniaAges 18 years+ - NCT06191133RecruitingPhase 1
Fenofibrate for cervical pre-cancer and cancer
This study tests whether a cholesterol-lowering drug called fenofibrate can help people with cervical pre-cancer or cancer. You take the drug before your scheduled surgery or chemoradiation, and doctors check if it reduces abnormal tissue or enhances treatment.
Cleveland, OhioAges 18 years+ - NCT06862960RecruitingPhase 2
Ozanimod for moderate Alzheimer's disease
This trial tests whether a daily pill called ozanimod can help people with moderate Alzheimer's disease. The study monitors changes in thinking and memory over time and requires a study partner who can join visits.
Fuzhou, FujianAges 55–80 - NCT06981026Recruiting
Checking if remote health coaching helps before prostate surgery
This study tests whether using a smartphone or computer to get health coaching before prostate cancer surgery helps people recover faster and have better results. You will be asked to exercise and track your health at home while staying connected with your care team.
OlomoucAges 40–80 - NCT06801184Recruiting
Gut bacteria study for constipation-predominant IBS with methane
This study looks at the gut bacteria in people with irritable bowel syndrome (IBS) who have constipation and produce high levels of methane gas. It aims to understand how methane relates to symptoms and may guide future treatments.
LyonAges 18 years+ - NCT06735820RecruitingPhase 1/Phase 2
MEK and MDM2 inhibitors for NF1-related tumors
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06095583RecruitingPhase 3
Toripalimab for limited-stage small cell lung cancer after chemoradiation
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
Harbin, HeilongjiangAges 18 years+ - NCT05460000RecruitingPhase 2
Niraparib after early ovarian cancer chemo—short vs long
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
InnsbruckAges 18 years+ - NCT07502300RecruitingPhase 3
New drug combo for advanced small cell lung cancer
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Zhengzhou, HenanAges 18 years+ - NCT05838521RecruitingPhase 2
IMMU-132 for cervical cancer that returned or did not go away
This trial studies IMMU-132 (sacituzumab govitecan) in people whose cervical cancer keeps coming back or stays after prior treatment. It aims to shrink tumors and improve outcomes after at least one chemotherapy has already been tried.
New Haven, ConnecticutAges 18 years+ - NCT06593431RecruitingPhase 3
Treating limited spread pancreatic cancer with local therapy
This trial tests whether combining local treatments (like radiation or surgery) with standard care can help people with pancreatic cancer that has spread to only a few spots (oligometastatic disease). The goal is to improve outcomes for this specific group of patients.
Camden, New JerseyAges 18 years+ - NCT07429773Recruiting
Immune markers in stubborn pelvic pain
This study looks at the immune system's response in people with chronic pelvic pain that hasn't gotten better with first treatments. By measuring certain immune markers, the researchers hope to better understand why the pain persists and find new ways to help.
Nice, Alpes-MaritimesAges 18–40 - NCT07509229Enrolling by invitationPhase 1/Phase 2
Algae Extract for Retinitis Pigmentosa
This study tests an extract from a type of algae that is rich in a special form of vitamin A. It may help improve vision for people with retinitis pigmentosa caused by certain gene mutations that affect how the eye processes vitamin A.
Tel LitwinskyAges 18 years+ - NCT07367282RecruitingPhase 4
Faricimab for newly diagnosed wet age-related macular degeneration
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
SeongnamAges 50 years+ - NCT07726199Recruiting
Neck treatment approaches for oral cancer without neck spread
This study compares different ways to treat the neck in patients with early-stage oral cancer that hasn't spread to the neck. The goal is to find which approach works best while keeping side effects low.
Kolhāpur, MaharashtraAges 21–75 - NCT07724925Recruiting
Comparing two arm therapies for stroke recovery
This study compares two types of arm and hand therapy for people recovering from a stroke. It aims to see which approach helps improve arm function and daily living skills.
Nankana SahibAges 45–70 - NCT07726108Recruiting
Digital triage to speed up emergency care
This trial tests a digital system that helps emergency staff quickly decide how to treat patients when they first arrive. It may help you get seen faster if you come in on your own, go through the normal check-in, and aren't sent directly to a special clinic.
Villars-sur-Glâne, Canton of FribourgAges 18 years+ - NCT06699771RecruitingPhase 1
Safety study of GCC2005 for NK and T-cell cancers
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Seoul, SeoulAges 19–80 - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+
Hear when a new Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient?
- Yes. Clin2 currently lists 14,836 recruiting patient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.